Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study

Transplant Proc. 2000 Nov;32(7):1721-2. doi: 10.1016/s0041-1345(00)01400-7.

Authors

K M Wong¹, C Y Cheung, Y H Chan, W L Chak, K S Choi, K F Chau, C S Li

Affiliation

¹ Renal Unit, Department of Medicine, Queen Elizabeth Hospital, SAR, Hong Kong, People's Republic of China.

PMID: 11119907
DOI: 10.1016/s0041-1345(00)01400-7

No abstract available

Publication types

Clinical Trial
Comparative Study
Controlled Clinical Trial

MeSH terms

Adult
Azathioprine / therapeutic use
Cadaver
Cause of Death
Cyclosporine / adverse effects
Cyclosporine / therapeutic use*
Drug Therapy, Combination
Female
Follow-Up Studies
Graft Rejection / epidemiology
Graft Rejection / pathology
Graft Survival / drug effects
Graft Survival / physiology*
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / immunology*
Kidney Transplantation / mortality
Kidney Transplantation / physiology
Male
Prednisolone / therapeutic use
Survival Rate
Tacrolimus / adverse effects
Tacrolimus / therapeutic use*
Time Factors
Tissue Donors

Substances

Immunosuppressive Agents
Cyclosporine
Prednisolone
Azathioprine
Tacrolimus